Kemp Proteins Selected to Provide Assay Development for Potential First-In-Class Therapy for Chronic Spinal Cord Injury

Share Article

Subcontract award by the Frederick National Laboratory, currently operated by Leidos Biomedical Research, Inc. as part of NIH’s National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program to assist ReNetX Bio’s AXER-204 FDA trial to promote recovery of neurological function in spinal cord injury patients

News Image
“We are delighted that the Frederick National Laboratory and the NCATS researcher team has selected Kemp Proteins to provide protein characterization and assay development for the AXER-204 drug." - Michael Keefe, CEO, Kemp Proteins

Kemp Proteins announced today its selection by the Frederick National Laboratory, currently operated by Leidos Biomedical Research, Inc. to provide Bio-Layer Interferometry Assay Development support for a novel Spinal Cord Injury (SCIs) therapy, called AXER-204. ReNetX Bio developed AXER-204 to promote recovery of neurological function through growth of axonal fibers after SCI. ReNetX Bio is an awardee of NIH’s BrIDGs Program, which provides critical resources for the development of new therapeutic agents, such as AXER-204.

To date, there is no FDA-approved therapeutic that promotes new connections between surviving nerve cells. Kemp Proteins is honored to join efforts with ReNetX Bio to achieve the unmet medical need for neurological recovery. An estimated 17,700 Spinal Cord Injuries (SCIs) occur every year in the United States, and approximately 288,000 Americans are living with SCIs. The ultimate goal of the drug is to allow victims of chronic SCI to regain function and to improve their quality of life.

Kemp Proteins will express and purify the ligands associated with the NCATs project and will develop a binding assay using bio-layer interferometry technology, which could potentially be used as a potency release assay for the AXER-204 therapy. Kemp Proteins will provide full kinetic analysis of protein interactions by determining real-time on-(ka) and off-(kd) rates and affinity constants (KD) of selected ligand-protein pairs for the AXER-204 program. Kemp Proteins is an ISO 9001:2015 bioservices company that assists clients in novel protein expression, custom monoclonal antibody development, assay design and development, and biomanufacturing of reagents for biopharmaceutical products.

“We are delighted that the Frederick National Laboratory and the NCATS researcher team has selected Kemp Proteins to provide protein characterization and assay development for the AXER-204 drug,” said Michael Keefe, CEO of Kemp Proteins. “Our goal is to provide a reliable assay for AXER-204, and in so doing, assist ReNetX to meet their developmental milestones and ultimately gain FDA approval to market this novel drug for SCI.”

About the Subcontract
This project is 100% supported with federal funds provided by the National Cancer Institute, National Institutes of Health, under Leidos Biomedical Research Inc.’s Prime Contract 75N91019D00024, Task Order 75N91019F00140. The subcontract total award amount is $154,052.50. The content of this press release does not necessarily reflect the views or policies of the U.S. Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

About Kemp Proteins (http://www.kempproteins.com)
Kemp Proteins, an ISO9001 ccompany, is a leading provider of gene-to-protein, hybridoma and cell line development services. For over 20 years, Kemp’s team of protein problem-solvers has delivered best-in-class services that optimize productivity and mitigate risk for life sciences innovators developing protein-based products, including human and veterinary diagnostics, biopharmaceuticals, and vaccines. Kemp Proteins is a Six.02 Bioservices member company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Hicks, Chief Operating Officer
Visit website